Keywords: phase, ii, trial, repligen, rpf4, started, study
PHASE II TRIAL OF REPLIGEN'S rPF4
Article | 06 December 1993
Repligen has started a Phase II study of its recombinant platelet factor 4 product for reversing heparin anticoagulation. The 40-patient, double-blind ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- US Supreme Court says patent settlement can "sometimes" be illegal
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
